Gene: ELOVL4

6785
ADMD|CT118|ISQMR|SCA34|STGD2|STGD3
ELOVL fatty acid elongase 4
protein-coding
6q14.1
Ensembl:ENSG00000118402 MIM:605512 Vega:OTTHUMG00000015087 UniprotKB:Q9GZR5
NG_009108.1
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
3.674e-2 (AD)  3.073e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
GLRB0.986
SYT40.976
NAP1L20.972
CADPS0.968
SNAP910.968
NSF0.967
MAP7D20.967
FBXL20.965
MAP2K40.964
REEP10.963

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CSAG1-0.579
FZD10-0.53
TFPI2-0.527
RNF135-0.526
MAGEA12-0.525
RAI14-0.521
REST-0.519
MYL3-0.516
RUNX3-0.512
CNN2-0.511

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB00132Alpha-Linolenic AcidSmall Molecule463-40-1Approved|NutraceuticalTarget
DB09328VayarinSmall MoleculeApproved|InvestigationalEnzyme
ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELOVL4 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELOVL4 mRNA"27188386
D000447AldehydesAldehydes results in increased expression of ELOVL4 mRNA25014914
D001280AtrazineAtrazine results in increased expression of ELOVL4 mRNA25929836
C022921benzo(k)fluoranthenebenzo(k)fluoranthene results in decreased expression of ELOVL4 mRNA26377693
D004958EstradiolEstradiol results in increased expression of ELOVL4 mRNA19484750
C006780bisphenol Abisphenol A results in decreased expression of ELOVL4 mRNA25181051
C018475butyraldehydebutyraldehyde results in increased expression of ELOVL4 mRNA26079696
D019327Copper SulfateCopper Sulfate affects the expression of ELOVL4 mRNA19549813
D002945Cisplatin[Cisplatin co-treated with RELB mutant form co-treated with TNF protein] results in increased expression of ELOVL4 mRNA23625948
C544151jinfukangjinfukang results in decreased expression of ELOVL4 mRNA27392435
C561695(+)-JQ1 compound(+)-JQ1 compound results in increased expression of ELOVL4 mRNA24796395
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of ELOVL4 mRNA23103053
C046012pentanalpentanal results in increased expression of ELOVL4 mRNA26079696
C027373potassium chromate(VI)potassium chromate(VI) results in increased expression of ELOVL4 mRNA22714537
D011374ProgesteroneProgesterone results in increased expression of ELOVL4 mRNA20631399
C005556propionaldehydepropionaldehyde results in increased expression of ELOVL4 mRNA26079696
C059514resveratrolresveratrol results in increased expression of ELOVL4 mRNA23419489
D015474IsotretinoinIsotretinoin results in decreased expression of ELOVL4 mRNA20436886
C089730rosiglitazonerosiglitazone results in increased expression of ELOVL4 mRNA23166672
D012822Silicon DioxideSilicon Dioxide analog results in increased expression of ELOVL4 mRNA23806026|2589566
D012822Silicon DioxideSilicon Dioxide results in increased expression of ELOVL4 mRNA25351596
D012834SilverSilver results in decreased expression of ELOVL4 mRNA27131904
C017947sodium arsenitesodium arsenite results in increased expression of ELOVL4 mRNA22714537
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of ELOVL4 mRNA23152189
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELOVL4 mRNA"27188386
C012589trichostatin Atrichostatin A results in decreased expression of ELOVL4 mRNA24935251|2627250
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in increased expression of ELOVL4 mRNA"26179874
D014520UrethaneUrethane results in increased expression of ELOVL4 mRNA28818685
D014635Valproic AcidValproic Acid affects the expression of ELOVL4 mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of ELOVL4 mRNA23179753|2718838
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of ELOVL4 gene25560391
D015034Zinc OxideZinc Oxide affects the expression of ELOVL4 mRNA28648595

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005515protein binding-IPI20937905  
GO:0008020G-protein coupled photoreceptor activity-NAS11138005  
GO:0009922fatty acid elongase activity-IBA21873635  
GO:01023363-oxo-arachidoyl-CoA synthase activity-IEA-  
GO:01023373-oxo-cerotoyl-CoA synthase activity-IEA-  
GO:01023383-oxo-lignoceronyl-CoA synthase activity-IEA-  
GO:0102756very-long-chain 3-ketoacyl-CoA synthase activity-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0006633fatty acid biosynthetic process-NAS11138005  
GO:0009584detection of visible light-IEA-  
GO:0019367fatty acid elongation, saturated fatty acid-IBA21873635  
GO:0019367fatty acid elongation, saturated fatty acid-IDA20937905  
GO:0030148sphingolipid biosynthetic process-IBA21873635  
GO:0034625fatty acid elongation, monounsaturated fatty acid-IBA21873635  
GO:0034626fatty acid elongation, polyunsaturated fatty acid-IBA21873635  
GO:0042761very long-chain fatty acid biosynthetic process-IBA21873635  
GO:0042761very long-chain fatty acid biosynthetic process-IDA20937905  
GO:0042761very long-chain fatty acid biosynthetic process-ISS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005783endoplasmic reticulum-IDA20937905  
GO:0030176integral component of endoplasmic reticulum membrane-IBA21873635  
GO:0030176integral component of endoplasmic reticulum membrane-IDA16036915  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-1430728MetabolismIEA
R-HSA-556833Metabolism of lipidsIEA
R-HSA-75105Fatty acyl-CoA biosynthesisIEA
R-HSA-75876Synthesis of very long-chain fatty acyl-CoAsIEA
R-HSA-8978868Fatty acid metabolismIEA

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
17210851Cigarette smoking, CFH, APOE, ELOVL4, and risk of neovascular age-related macular degeneration. (2007 Jan)DeAngelis MMArch Ophthalmol